Home » Topics » Regulatory » EMA

EMA
RSS

EMA to review Vivus' MAA for avanafil in ED

March 26, 2012

EMA validates Raptor's MAA for RP-103

March 26, 2012

EMA accepts lomitapide MAA for review

March 21, 2012

Novartis withdraws applications for new rivastigmine indication

March 16, 2012

Alkermes Pharma Ireland withdraws megestrol MAA

March 15, 2012

Endocyte to file conditional MAAs in E.U. for anticancer therapeutic and imaging agent

March 15, 2012

EMA grants orphan drug status to Cytokinetics drug in ALS

March 7, 2012

Affymax to receive milestone payment related to peginesatide

Feb. 28, 2012

EMA accepts Takeda's MAA for peginesatide

Feb. 27, 2012

EMA accepts Genzyme's teriflunomide MAA

Feb. 24, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...